Wiring the oncogenic circuitry: Pin1 unleashes mutant p53

Oncotarget

Volumn 2, Issue 9, 2011, Pages 654-

  Napoli, Marco ^a,b   Girardini, Javier E ^c   Piazza, Silvano ^a   Del Sal, Giannino ^a,b  

^a Laboratorio Nazionale CIB LNCIB   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

^c Instituto de Biologia Molecular y Celular de Rosario   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDYLPROLYL ISOMERASE PIN1; PROTEIN P53; NIMA INTERACTING PEPTIDYLPROLYL ISOMERASE; NIMA-INTERACTING PEPTIDYLPROLYL ISOMERASE; PEPTIDYLPROLYL ISOMERASE;

BREAST CANCER; CANCER PROGNOSIS; CARCINOGENESIS; ENZYME ACTIVITY; GENE EXPRESSION; GENE MUTATION; HUMAN; MUTANT; NONHUMAN; NOTE; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; ANIMAL; ARTICLE; BREAST TUMOR; CELL TRANSFORMATION; FEMALE; GENETICS; METABOLISM; MOUSE;

ANIMALS; BREAST NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HUMANS; MICE; PEPTIDYLPROLYL ISOMERASE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84055203847     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.329     Document Type: Note

References (12)

1. Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis. Genes & Cancer 2011; 2: 466-74.
2. Caulin C, Nguyen T, Lang GA, Goepfert TM, Brinkley BR, Cai WW, Lozano G, Roop DR. An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations. J Clin Invest 2007; 117: 1893-1901.
3. Song H, Hollstein M, Xu Y. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat Cell Biol 2007; 9: 573-580.
4. Terzian T, Suh YA, Iwakuma T, Post SM, Neumann M, Lang GA, Van Pelt CS, Lozano G. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev 2008; 22: 1337-1344.
5. Girardini JE, Napoli M, Piazza S, Rustighi A, Marotta C, Radaelli E, Capaci V, Jordan L, Quinlan P, Thompson A, Mano M, Rosato A, Crook T, Scanziani E, Means AR, Lozano G, Schneider C, Del Sal G. A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell 2011; 20, 79-91.
6. Zacchi P, Gostissa M, Uchida T, Salvagno C, Avolio F, Volinia S, Ronai Z, Blandino G, Schneider C, Del Sal, G. The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults. Nature 2002; 419: 853-857.
7. Zheng H, You H, Zhou XZ, Murray SA, Uchida T, Wulf G, Gu L, Tang X, Lu KP, Xiao ZX. The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response. Nature 2002; 419: 849-853.
8. Wulf GM, Liou YC, Ryo A, Lee SW, Lu KP. Role of Pin1 in the regulation of p53 stability and p21 transactivation, and cell cycle checkpoints in response to DNA damage. J Biol Chem. 2002; 277: 47976-9.
9. Mantovani F, Tocco F, Girardini JE, Smith P, Gasco M, Lu X, Crook T, Del Sal G. The prolyl isomerase Pin1 orchestrates p53 acetylation and dissociation from the apoptosis inhibitor iASPP. Nat Struct Mol Biol 2007; 14: 912-920.
10. Berger M, Stahl N, Del Sal G, Haupt Y. Mutations in proline 82 of p53 impair its activation by Pin1 and Chk2 in response to DNA damage. Mol Cell Biol 2005; 25: 5380- 5388.
11. Ivshina AV, George J, Senko O, Mow B, Putti TC, Smeds J, Lindahl T, Pawitan Y, Hall P, Nordgren H, Wong JE, Liu ET, Bergh J, Kuznetsov VA, Miller LD. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res. 2006; 66: 10292- 301.
12. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene. 2007; 26: 2157-65.